Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07812246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

Name: Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial — clinical trial record (NCT07812246)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorCity of Hope Medical Center

Started2027-08-04

View on ClinicalTrials.gov ↗

City of Hope Medical Center

385 trials monitored

See 43 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Chronic Lymphocytic Leukemia (CLL)

451 trials monitored

See 32 trials at risk

This phase II trial tests how well giving zanubrutinib and sonrotoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) that has come back after a period of improvement (relapsed). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) and BCL-XL inhibitors. It may stop the growth of tumor cells and may kill them by blocking Bcl-2 and Bcl-XL, proteins needed for cell survival. Giving zanubrutinib and sonrotoclax may work well for the treatment of relapsed CLL/SLL.

Trial Details

NCT Number	NCT07812246
Lead Sponsor	City of Hope Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment	44 participants
Start Date	2027-08-04
Primary Completion	2028-08-13 (estimated)
Study Completion	2028-08-13 (estimated)
Updated on ClinicalTrials.gov	2026-09-10